Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease

Szczegóły
Opis

Tytuł:: Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
Autorzy:: Soran Peshbahar
Elisabeth Bendstrup
Temat:: inflammatory autoimmune myopathy
polymyositis (pm)
dermatomyositis (dm)
antisynthetase syndrome
interstitial lung disease (ild)
intravenous immunoglobulin (ivig)
Diseases of the respiratory system
RC705-779
Źródło:: European Clinical Respiratory Journal, Vol 7, Iss 1 (2020)
Wydawca:: Taylor & Francis Group, 2020.
Rok publikacji:: 2020
Kolekcja:: LCC:Diseases of the respiratory system
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 2001-8525
20018525
Relacje:: https://doaj.org/toc/2001-8525
DOI:: 10.1080/20018525.2020.1840706
Dostęp URL:: https://doaj.org/article/fc3b71d619f6464686b88c0495984cda Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.fc3b71d619f6464686b88c0495984cda
: Czasopismo naukowe

Full Text Finder

Polymyositis (PM) and dermatomyositis (DM) are subtypes of autoimmune inflammatory myopathies. Interstitial lung disease (ILD) involvement is common in PM/DM. There is no evidence base for immunosuppression in DM/PM-ILD and current evidence is based on case stories and expert opinions. We present a 63-year-old male with severe respiratory failure due to PM-ILD who was treated successfully with intravenous immunoglobulin, recovered the acute phase and survived more than 4 years.

Informacja